20/20 Biolabs, Inc. (AIDX) stock analysis
Close on Nov 11, 2026Market cap $2.87MP/E –Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Weak6 of 30 checks passed
20/20 Biolabs passes 6 of the 30 checks behind our score; 19 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 3/6
- Growth
- 2/6
- Past performance
- 0/6
- Financial health
- 1/6
- Dividend
- 0/6
What stands out
Margin of safety over 20%
The price is 59.3% below fair value, more than the 20% cushion we look for.
Trading below fair value
The share price of $0.22 is below our fair value estimate of $0.55.
P/B below the industry
20/20 Biolabs's price-to-book of 1.77 is below the Engineering, Accounting, Research, Management, and Related Services median of 3.70.
Growing faster than the industry
Revenue grew 16.7% over the last twelve months; the Engineering, Accounting, Research, Management, and Related Services median is 6.6%.
What to watch
Interest not well covered
Operating income covers interest expense -21.3 times; we look for at least 5.
Elevated bankruptcy risk
The Altman Z-score is -8.83; above 3 is the safe zone and below 1.8 the distress zone.
Return on equity below the industry
20/20 Biolabs's return on equity of -239% is below the Engineering, Accounting, Research, Management, and Related Services median of -10.2%.
Net margin below the industry
20/20 Biolabs's net margin of -183% is below the Engineering, Accounting, Research, Management, and Related Services median of -53.6%.
Valuation3/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B below the industry
20/20 Biolabs's price-to-book of 1.77 is below the Engineering, Accounting, Research, Management, and Related Services median of 3.70.
Trading below fair value
The share price of $0.22 is below our fair value estimate of $0.55.
Margin of safety over 20%
The price is 59.3% below fair value, more than the 20% cushion we look for.
Growth2/6
Revenue growth over 3 years
Needs three years of positive revenue.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growing faster than the industry
Revenue grew 16.7% over the last twelve months; the Engineering, Accounting, Research, Management, and Related Services median is 6.6%.
Company guidance
No outlook found in earnings releases from the last twelve months.
Gross margin improving
Gross margin was 29.6% over the last twelve months, against 20.6% a year earlier.
Past performance0/6
Return on equity
Needs positive equity and five years of results.
Return on invested capital
Needs operating income and invested capital.
Return on equity below the industry
20/20 Biolabs's return on equity of -239% is below the Engineering, Accounting, Research, Management, and Related Services median of -10.2%.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin against its history
Needs five years of revenue and net income.
Net margin below the industry
20/20 Biolabs's net margin of -183% is below the Engineering, Accounting, Research, Management, and Related Services median of -53.6%.
Financial health1/6
Debt level
Needs debt and equity figures.
Debt trend
Needs a balance sheet from five years ago with positive equity.
Debt coverage
Needs operating cash flow.
Interest not well covered
Operating income covers interest expense -21.3 times; we look for at least 5.
Short-term assets cover short-term debts
Current assets are 1.99 times current liabilities.
Elevated bankruptcy risk
The Altman Z-score is -8.83; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
20/20 Biolabs has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itOur estimate per share
$0.55
The share price is 59% below this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| P/B | 3.7× | – | 3.7× | $0.47 | 50% |
| P/S | 4.0× | – | 4.0× | $0.64 | 50% |
| Fair value | $0.55 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
High risk
- Average value traded per day
- $52.48K
- Value traded per 1% price move
- $7.07K
Downside
- Typical loss in a bad month
- –
- Volatility (annualized)
- 129%
- Sharpe ratio, 1 year
- –
- Beta to the S&P 500 (5Y)
- –
Margins
Share of revenue, fiscal years 2023 to 2025
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +16.7% | – | – | – | |
| Gross profit | +67.8% | – | – | – |
Returns and balance sheet
3 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2023 | FY2023 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -503.1% | |
| Current ratio | – | – | 0.60 | |
| Interest coverage | – | – | -21.3× | |
| Diluted shares | – | – | 5M |
Cash use needs five years of cash flow figures
20/20 Biolabs does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -182.8% | 0.53× | 5.20× | -503.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero-$3.74M
- Cash generatingOperating cash flow above zero-$1.92M
- Return on assets improvedROA up on the prior year– → -104.3%
- Earnings backed by cashOperating cash flow above net income-$1.92M vs -$3.74M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.50 → 0.60
- No dilutionShare count did not rise5M → 5M
- Gross margin improvedGross margin up on the prior year20.56% → 29.56%
- More efficientAsset turnover rose– → 0.57
See a number that looks wrong?